Medtronic plc (LON:0Y6X)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 87.66B -1.1% |
| Revenue (ttm) | 26.93B +8.4% |
| Net Income | 3.56B +3.0% |
| EPS | 2.76 +3.3% |
| Shares Out | n/a |
| PE Ratio | 24.65 |
| Forward PE | 15.63 |
| Dividend | 2.17 (3.17%) |
| Ex-Dividend Date | Sep 25, 2026 |
| Volume | 1,073 |
| Open | 90.80 |
| Previous Close | 92.86 |
| Day's Range | 90.80 - 95.00 |
| 52-Week Range | 73.00 - 106.66 |
| Beta | 0.57 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Sep 1, 2026 |
About Medtronic
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. It operates through three segments: The Cardiovascular Portfolio, Neuroscience Portfolio, and Medical Surgical Portfolio. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and rem... [Read more]
Financial Performance
In fiscal year 2026, Medtronic's revenue was $36.36 billion, an increase of 8.43% compared to the previous year's $33.54 billion. Earnings were $4.80 billion, an increase of 2.98%.
Financial numbers in USD Financial StatementsNews
Medtronic announces cash dividend for second quarter of fiscal year 2027
GALWAY, Ireland, Aug. 20, 2026 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE:MDT) on Thursday, August 20, 2026, approved the company's cash dividend for the second quarter of fiscal ye...
Medtronic Proxy statement: Proxy filing
Medtronic filed a proxy statement on August 17, 2026, providing details for shareholder voting and corporate governance matters.
Medtronic Proxy statement: Proxy filing
Medtronic filed a proxy statement on August 17, 2026, providing details for shareholder voting and corporate governance matters.
Medtronic announces CE Mark indication for Affera Mapping and Ablation System
Medtronic (MDT) announced an expanded CE Mark indication for the Affera Mapping and Ablation System with Sphere-9 Catheter to treat ventricular arrhythmias, including ventricular tachycardia and prema...
Medtronic announces expanded CE Mark indication for Affera™ Mapping and Ablation System and Sphere-9™ Catheter for treatment of ventricular arrhythmias
Sphere-9 all-in-one mapping and ablation, large-tip focal, dual energy catheter first to be CE Marked for ventricular ablation New indication marks important milestone for ventricular arrhythmia patie...
Medtronic put volume heavy and directionally bearish
Bearish flow noted in Medtronic (MDT) with 4,403 puts trading, or 3x expected. Most active are 8/7 weekly 85 puts and 8/7 weekly 86 puts, with total volume in those…
Medtronic upgraded to Buy from Neutral at UBS
UBS upgraded Medtronic (MDT) to Buy from Neutral with a price target of $100, up from $85. A turnaround is underway at Medtronic, the analyst tells investors in a research…
A new era for surgery with real-time AI: Medtronic to unveil Touch Surgery™ Aide, the next-generation compute platform for the operating room at Society of Robotic Surgery 2026
Advanced compute power, built on NVIDIA infrastructure, enables real-time decision support during the procedure FDA-cleared Instrument Exit Point (IEP), the first real-time AI application for robotic ...
Medtronic to announce financial results for its first quarter of fiscal year 2027
GALWAY, Ireland, July 20, 2026 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that it will report financial results on Tuesday, September 1, 2026,...
Medtronic acquisition of SPR expected to be minimally dilutive to FY27 EPS
Medtronic (MDT) announced it has completed its acquisition of SPR Therapeutics, a privately held medical technology company and recognized leader in short-term, percutaneous peripheral nerve stimulati...
Medtronic completes acquisition of SPR, expanding patient access to minimally invasive, non-opioid treatment of chronic and acute pain
Acquisition adds category-defining SPRINT® PNS technology to Medtronic's pain therapy portfolio—the broadest in the industry.¹ GALWAY, Ireland, July 16, 2026 /PRNewswire/ -- Medtronic plc (NYSE: MDT),...
Medtronic price target raised to $91 from $90 at BTIG
BTIG analyst Ryan Zimmerman raised the firm’s price target on Medtronic (MDT) to $91 from $90 and keeps a Buy rating on the shares as part of a broader research…
Leerink sees CPT proposal as ‘clear net positive’ signal for Medtronic
Leerink notes that the AMA CPT Editorial Panel released the Proposed Panel Agenda for their September 2026 CPT Editorial Panel Meeting and will review a proposal to establish Category I…
Medtronic price target lowered to $100 from $119 at TD Cowen
TD Cowen lowered the firm’s price target on Medtronic (MDT) to $100 from $119 and keeps a Buy rating on the shares. The firm expects CAS to be the primary…
Medtronic price target lowered to $105 from $106 at Evercore ISI
Evercore ISI lowered the firm’s price target on Medtronic (MDT) to $105 from $106 and keeps an Outperform rating on the shares. The firm’s Q2 preview for MedTech, Life Sciences…
This Undervalued Medical-Devices Stock Is Poised for a Rebound
Medtronic offers high growth potential in addition to discounted valuation.
Medtronic completes acquisition of Scientia Vascular, seamlessly integrating access and therapeutic portfolios for neurovascular care
Acquisition delivers simplicity and access, supporting physicians across the full procedural workflow GALWAY, Ireland, June 12, 2026 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healt...
Medtronic price target lowered to $95 from $110 at BofA
BofA lowered the firm’s price target on Medtronic (MDT) to $95 from $110 and keeps a Buy rating on the shares. Noting that the firm’s services team continues to highlight…
As Tech Stocks Slide, The Healthcare Sector Shines. Why Some Experts Say They Like This Defensive Play
Tech stocks are pulling back, and healthcare is surging.
Medtronic price target lowered to $83 from $84 at Goldman Sachs
Goldman Sachs analyst David Roman lowered the firm’s price target on Medtronic (MDT) to $83 from $84 and keeps a Neutral rating on the shares. The company’s Q4 results carried…
Medtronic price target lowered to $97 from $112 at Bernstein
Bernstein analyst Lee Hambright lowered the firm’s price target on Medtronic (MDT) to $97 from $112 and keeps an Outperform rating on the shares following a solid Q4. After weaker…
Medtronic Earnings Call Transcript: Q4 2026
Q4 and FY26 delivered strong revenue and EPS growth, with robust performance across key segments and significant progress in innovation and portfolio focus. FY27 guidance anticipates continued top-line acceleration, margin leverage, and ongoing investment despite tariff and macro headwinds.